James Edgemond - 15 May 2024 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Reporting relationship: CFO AND TREASURER
Issuer ticker: UTHR
Reported as of: 15 May 2024
Net transaction value: -$4,393,102
SEC form: 4
Accepted by SEC: 16 May 2024, 16:30:26 UTC
Prior SEC filing: 26 Feb 2026
Next SEC filing: 20 Aug 2024
Source filing: View source filing
Reporting owner signature: /s/ John S. Hess, Jr. under Power of Attorney

Key filing fact

James Edgemond filed Form 4 for UNITED THERAPEUTICS Corp (UTHR) on 16 May 2024.

Key facts

This page summarizes James Edgemond's Form 4 filing for UNITED THERAPEUTICS Corp (UTHR).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 16 May 2024, 16:30.

Change

Previous filing in this sequence was filed on 26 Feb 2026.
Current net transaction value: -$4,393,102.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

UTHR transaction

Common Stock

Options Exercise

Transaction value: $4,082,500
Shares: +25,000
Change %: +1584%
Price: $163.30
Shares after: 26,578
Date: 15 May 2024
Ownership: Direct
Footnotes: F1

UTHR transaction

Common Stock

Sale

Transaction value: $6,817,250
Shares: -25,000
Change %: -94%
Price: $272.69
Shares after: 1,578
Date: 15 May 2024
Ownership: Direct

UTHR transaction

Common Stock

Options Exercise

Transaction value: $2,475,628
Shares: +15,160
Change %: +961%
Price: $163.30
Shares after: 16,738
Date: 15 May 2024
Ownership: Direct

UTHR transaction

Common Stock

Sale

Transaction value: $4,133,980
Shares: -15,160
Change %: -91%
Price: $272.69
Shares after: 1,578
Date: 15 May 2024
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

UTHR transaction Derivative

Share Tracking Award

Options Exercise

Transaction value: $0
Shares: -25,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 May 2024
Ownership: Direct
Underlying class: Share Tracking Award
Underlying amount: 25,000
Exercise price: $163.30
Footnotes: F2

UTHR transaction Derivative

Share Tracking Award

Options Exercise

Transaction value: $0
Shares: -15,160
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 May 2024
Ownership: Direct
Underlying class: Share Tracking Award
Underlying amount: 15,160
Exercise price: $163.30
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Includes 26, 59, 47, and 62 shares of common stock acquired on September 2, 2022, March 3, 3023, September 1, 2023, and March 4, 2024, respectively, under the United Therapeutics Corporation Employee Stock Purchase Plan.

Footnote F2

Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.